Published in Clin Cancer Res on November 01, 2006
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res (2009) 4.02
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol (2010) 1.80
GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol (2008) 1.68
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer (2010) 1.54
Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res (2012) 1.20
Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res (2008) 1.11
Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol (2009) 1.05
Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol (2011) 1.03
The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology (2011) 1.02
Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements. Drug Metab Dispos (2007) 0.96
Integrative disease classification based on cross-platform microarray data. BMC Bioinformatics (2009) 0.94
Clinico-Pathological Characteristics of Triple Negative and Non Triple Negative High Grade Breast Carcinomas with and Without Basal Marker (CK5/6 and EGFR) Expression at a Rural Tertiary Hospital in India. Breast Cancer (Auckl) (2012) 0.92
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). Biomed Rep (2013) 0.90
Automatic tumor-stroma separation in fluorescence TMAs enables the quantitative high-throughput analysis of multiple cancer biomarkers. PLoS One (2011) 0.89
Biclustering reveals breast cancer tumour subgroups with common clinical features and improves prediction of disease recurrence. BMC Genomics (2013) 0.85
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. Br J Cancer (2012) 0.84
Differential expression of arrestins is a predictor of breast cancer progression and survival. Breast Cancer Res Treat (2011) 0.83
Development of DNA damage response signaling biomarkers using automated, quantitative image analysis. J Histochem Cytochem (2013) 0.83
Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer. BMC Cancer (2014) 0.82
Quantitative assessment of tissue biomarkers and construction of a model to predict outcome in breast cancer using multiple imputation. Cancer Inform (2008) 0.81
Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncol Lett (2013) 0.80
A texture based pattern recognition approach to distinguish melanoma from non-melanoma cells in histopathological tissue microarray sections. PLoS One (2013) 0.80
The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities. Int J Proteomics (2011) 0.78
A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat (2016) 0.77
A Comparison of Clinical Features, Pathology and Outcomes in Various Subtypes of Breast Cancer in Indian Women. J Clin Diagn Res (2015) 0.76
Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines. Cancer Med (2015) 0.76
Prognostic and clinicopathological value of GATA binding protein 3 in breast cancer: A systematic review and meta-analysis. PLoS One (2017) 0.75
The Applications of Genetic Algorithms in Medicine. Oman Med J (2015) 0.75
ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. Physiol Genomics (2016) 0.75
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res (2004) 6.22
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23
A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med (2015) 4.07
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst (2005) 3.62
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol (2004) 2.74
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst (2006) 2.71
Long-term preservation of antigenicity on tissue microarrays. Lab Invest (2004) 2.44
A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol (2008) 2.43
Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A (2009) 2.41
Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell (2011) 2.23
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell (2011) 2.17
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer (2012) 2.16
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol (2003) 2.07
Interpretative problems and preparative technique influence reliability of intraoperative parathyroid touch imprints. Arch Pathol Lab Med (2003) 2.02
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99
Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest (2011) 1.96
Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res (2003) 1.96
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov (2012) 1.94
Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res (2006) 1.91
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol (2008) 1.89
High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res (2007) 1.88
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res (2006) 1.87
Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science (2009) 1.83
Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol (2009) 1.81
Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res (2004) 1.80
Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res (2003) 1.75
Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood (2007) 1.73
Utility of multispectral imaging for nuclear classification of routine clinical histopathology imagery. BMC Cell Biol (2007) 1.72
Isolation and characterization of progenitor-like cells from human renal proximal tubules. Am J Pathol (2011) 1.72
Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res (2002) 1.69
Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res (2011) 1.69
Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg (2010) 1.68
Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med (2006) 1.65
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res (2007) 1.62
In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol (2010) 1.62
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol (2008) 1.61
A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle (2011) 1.60
Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res (2008) 1.59
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res (2011) 1.56
Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol (2011) 1.54
Retracted Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res (2010) 1.51
Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med (2010) 1.51
Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res (2008) 1.50
Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res (2005) 1.49
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer (2005) 1.45
Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 1.44
Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest (2007) 1.42
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene (2005) 1.42
Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res (2005) 1.42
Increasing cytotechnologist workload above 100 slides per day using the BD FocalPoint GS imaging system negatively affects screening performance. Am J Clin Pathol (2012) 1.42
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst (2012) 1.42
Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann Thorac Surg (2004) 1.40
Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. Diagn Pathol (2012) 1.38
Pathological examination of sentinel lymph node in breast cancer: potential problems and possible solutions. Microsc Res Tech (2002) 1.38
Translational crossroads for biomarkers. Clin Cancer Res (2005) 1.38
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat (2013) 1.38
Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch Pathol Lab Med (2009) 1.37
Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology (2009) 1.36
Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J (2003) 1.35
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res (2006) 1.35
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol (2009) 1.34
Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev (2010) 1.34